Back to dashboard
MedicaidPrior AuthMedium impact

MAB2022110802

Pennsylvania Medicaid (DHS)·PA · Pulmonology, Rheumatology, Pharmacy·Provider Bulletin
Effective date
Jan 9, 2023
We identified it
Jun 20, 2026
Days to comply

Summary

Pennsylvania's Medical Assistance program is updating prior authorization requirements for Antifibrotic Respiratory Agents (formerly called IPF Agents), removing drug interaction guidelines and renaming the therapeutic class. All prescriptions for these medications still require prior authorization with specific medical necessity criteria.

Action Required

Action needed
By January 9, 2023: Billing team should update any internal references from 'Idiopathic Pulmonary Fibrosis (IPF) Agents' to 'Antifibrotic Respiratory Agents' in billing systems and prior authorization workflows. Review updated medical necessity guidelines to ensure proper documentation is obtained from pulmonologists or rheumatologists before submitting prior authorization requests for Pennsylvania Medical Assistance patients.